PMEL and cancer: Melanoma was the first model to reveal CD4+ and CD8+ cellular specificity to cancer differentiation antigens gp100 and tyrosinase [88,89], suggesting the immunogenicity of the tumor and the ability of the patient’s own immune system to recognize and activate a specific immune response against cancer cells.